Biopharma | May 20, 2026
IGI’s new drug candidate ISB 2301 to target solid tumors
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Innovent will supply sintilimab for the collaborated clinical trial
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
